Related Experiment Video
Updated: May 17, 2025

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
Predictors in Optic Pathway Gliomas in Neurofibromatosis Type 1: A Single Center Study
Agata Marjańska1, Jagoda Styczyńska1, Agnieszka Jatczak-Gaca1
1Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Jurasz University Hospital, 85-095 Bydgoszcz, Poland.
This study analyzed 92 patients with Neurofibromatosis type 1-optic pathway gliomas (NF1-OPGs), finding amblyopia and proptosis predict the need for oncological treatment. Management guidelines suggest modified MRI protocols and careful monitoring before initiating therapy.
Area of Science:
- Neuro-oncology
- Ophthalmology
- Genetics
Background:
- Optic pathway gliomas (OPGs) are common NF1-dependent tumors.
- Retrospective analysis of NF1-OPG course, treatment indications, and outcomes is crucial.
Purpose of the Study:
- To analyze the clinical course, treatment indications, and therapeutic effects in 92 patients with NF1-OPGs.
- To identify factors influencing treatment decisions and outcomes in NF1-OPGs.
Main Methods:
- Retrospective analysis of demographics, clinical, genetic, imaging, and ophthalmological data.
- Multivariate analysis to identify significant factors for treatment and amblyopia.
- Evaluation of first and subsequent line oncological treatments.
Main Results:
- OPGs were unilateral in 55.4% and bilateral in 44.6% of patients.
- Oncological treatment was needed for 16.3%, with amblyopia and proptosis as significant predictors.
- Factors like strabismus, epilepsy, and optic nerve thickness influenced amblyopia development.
Conclusions:
- Modified MRI protocols are suggested: first MRI after age 1, reduced follow-up frequency for isolated cases, and no contrast for routine follow-ups.
- Caution is advised before initiating oncological therapy for visual acuity loss without confirmed progression on OCT, VEP, and MRI in specific patient groups.
More Related Videos
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023